Search research articles
Contact Us
Filters
Showing results (91-100 of 122) with videos related to
Page
of 13
Sort By:
British Journal of Haematology
|
February 5, 2020
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Lasse H Jakobsen, Fredrik Ellin, Knut B Smeland, et al.
JAMA Oncology
|
May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy
Chelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
British Journal of Haematology
|
September 30, 2016
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement
Tarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, et al.
Blood Advances
|
June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO
Jeremy S Abramson, William Townsend, Christopher P Fox, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2017
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy
Tarec Christoffer El-Galaly, Diego Villa, Thomas Yssing Michaelsen, et al.
Haematologica
|
February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
Allison Barraclough, James T England, Diego Villa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)
Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Blood
|
October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Jennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Blood
|
July 5, 2022
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
Chiara Rusconi, Chan Y Cheah, Toby A Eyre, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 122) with videos related to
Sort By:
Page
of 13
British Journal of Haematology
|
February 5, 2020
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Lasse H Jakobsen, Fredrik Ellin, Knut B Smeland, et al.
JAMA Oncology
|
May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy
Chelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
British Journal of Haematology
|
September 30, 2016
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement
Tarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, et al.
Blood Advances
|
June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO
Jeremy S Abramson, William Townsend, Christopher P Fox, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2017
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy
Tarec Christoffer El-Galaly, Diego Villa, Thomas Yssing Michaelsen, et al.
Haematologica
|
February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
Allison Barraclough, James T England, Diego Villa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)
Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Blood
|
October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Jennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Blood
|
July 5, 2022
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
Chiara Rusconi, Chan Y Cheah, Toby A Eyre, et al.
Page
of 13